{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:39:19Z","timestamp":1792658359727,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04595-z","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:51:36Z","timestamp":1792655496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Do progression-free survival benefits justify increased toxicity and treatment burden? A meta-regression analysis of phase III immune checkpoint inhibitor trials from a value-based oncology perspective"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7229-0100","authenticated-orcid":false,"given":"Long","family":"Zhenyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Tiantian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yuqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"2","key":"4595_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nri727","volume":"2","author":"AH Sharpe","year":"2002","unstructured":"Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116\u201326. https:\/\/doi.org\/10.1038\/nri727.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"4595_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367.","journal-title":"Cancer Discov"},{"issue":"6230","key":"4595_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172.","journal-title":"Science"},{"issue":"8","key":"4595_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","volume":"26","author":"NI Cherny","year":"2015","unstructured":"Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdv249.","journal-title":"Ann Oncol"},{"issue":"6","key":"4595_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamaoncol.2016.5296","volume":"3","author":"S Mailankody","year":"2017","unstructured":"Mailankody S, Prasad V. Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world. JAMA Oncol. 2017;3(6):843\u20134. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5296.","journal-title":"JAMA Oncol"},{"issue":"3","key":"4595_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pst.207","volume":"5","author":"T Burzykowski","year":"2006","unstructured":"Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat. 2006;5(3):173\u201386. https:\/\/doi.org\/10.1002\/pst.207.","journal-title":"Pharm Stat"},{"issue":"10","key":"4595_CR7","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","volume":"30","author":"CM Booth","year":"2012","unstructured":"Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable. J Clin Oncol. 2012;30(10):1030\u20133. https:\/\/doi.org\/10.1200\/JCO.2011.38.7571.","journal-title":"J Clin Oncol"},{"issue":"7414","key":"4595_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"4595_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ctrv.2017.12.004","volume":"63","author":"YK Chae","year":"2018","unstructured":"Chae YK, Galvez C, Anker JF, Iams WT, Bhave M. Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors. Cancer Treat Rev. 2018;63:116\u201321. https:\/\/doi.org\/10.1016\/j.ctrv.2017.12.004.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"4595_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000308","volume":"8","author":"SL Mushti","year":"2020","unstructured":"Mushti SL, Mulkey F, Sridhara R, Pazdur R, Singh H. Time to event analyses in immuno-oncology trials. J Immunother Cancer. 2020;8(1):e000308. https:\/\/doi.org\/10.1136\/jitc-2019-000308.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4595_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"issue":"6","key":"4595_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","volume":"180","author":"EY Chen","year":"2020","unstructured":"Chen EY, Haslam A, Prasad V. FDA acceptance of surrogate end points for cancer drug approval: 1992-2019. JAMA Intern Med. 2020;180(6):912\u20134. https:\/\/doi.org\/10.1001\/jamainternmed.2020.1097.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"4595_CR13","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","volume":"175","author":"C Kim","year":"2015","unstructured":"Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992\u20134. https:\/\/doi.org\/10.1001\/jamainternmed.2015.5868.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"4595_CR14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMhpr0807774","volume":"360","author":"PB Bach","year":"2009","unstructured":"Bach PB. Limits on Medicare\u2019s ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626\u201333. https:\/\/doi.org\/10.1056\/NEJMhpr0807774.","journal-title":"N Engl J Med"},{"issue":"8","key":"4595_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.04.013","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): primary analysis. J Thorac Oncol. 2020;15(8):1351\u201360. https:\/\/doi.org\/10.1016\/j.jtho.2020.04.013.","journal-title":"J Thorac Oncol"},{"issue":"21","key":"4595_CR16","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369\u201379. https:\/\/doi.org\/10.1200\/JCO.20.00793.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4595_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1816047.","journal-title":"N Engl J Med"},{"issue":"12","key":"4595_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923.","journal-title":"JAMA Oncol"},{"issue":"4","key":"4595_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy: immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195\u2013207. https:\/\/doi.org\/10.1038\/nrendo.2016.205.","journal-title":"Nat Rev Endocrinol"},{"issue":"7109","key":"4595_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"25","key":"4595_CR21","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMra1712502","volume":"379","author":"CL Shapiro","year":"2018","unstructured":"Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379(25):2438\u201350. https:\/\/doi.org\/10.1056\/NEJMra1712502.","journal-title":"N Engl J Med"},{"issue":"12","key":"4595_CR22","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","volume":"140","author":"T Fojo","year":"2014","unstructured":"Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics: the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1225\u201336. https:\/\/doi.org\/10.1001\/jamaoto.2014.1570.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"5","key":"4595_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.2074","volume":"19","author":"A Ali","year":"2016","unstructured":"Ali A. Cancer immunotherapy with checkpoint inhibitors is associated with immune-mediated reactions: a pharmacovigilance study. Value Health. 2016;19(5):A389. https:\/\/doi.org\/10.1016\/j.jval.2016.09.2074.","journal-title":"Value Health"},{"issue":"23","key":"4595_CR24","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","volume":"33","author":"LE Schnipper","year":"2015","unstructured":"Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563\u201377. https:\/\/doi.org\/10.1200\/JCO.2015.61.6706.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4595_CR25","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/annonc\/mdx342","volume":"28","author":"NI Cherny","year":"2017","unstructured":"Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2348\u201368. https:\/\/doi.org\/10.1093\/annonc\/mdx342.","journal-title":"Ann Oncol"},{"key":"4595_CR26","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.2147\/OTT.S151276","volume":"11","author":"G Cicero","year":"2018","unstructured":"Cicero G, De Luca R, Dieli F. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer. OncoTargets Ther. 2018;11:3059\u201363. https:\/\/doi.org\/10.2147\/OTT.S151276.","journal-title":"OncoTargets Ther"},{"key":"4595_CR27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-023-10613-y","volume":"23","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Xie C, Gao T, Yang Y, Yang Y, Zhao L. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced non-small cell lung cancer. BMC Cancer. 2023;23:678. https:\/\/doi.org\/10.1186\/s12885-023-10613-y.","journal-title":"BMC Cancer"},{"issue":"11","key":"4595_CR28","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/s41416-020-0805-y","volume":"122","author":"L Belin","year":"2020","unstructured":"Belin L, Tan A, De Rycke Y, Dechartres A. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review. Br J Cancer. 2020;122(11):1707\u201314. https:\/\/doi.org\/10.1038\/s41416-020-0805-y.","journal-title":"Br J Cancer"},{"key":"4595_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4595_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4595_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. John Wiley & Sons; 2009."},{"issue":"1","key":"4595_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","volume":"1","author":"M Buyse","year":"2000","unstructured":"Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1(1):49\u201367. https:\/\/doi.org\/10.1093\/biostatistics\/1.1.49.","journal-title":"Biostatistics"},{"issue":"1","key":"4595_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/biostatistics\/kxac044","volume":"25","author":"Q Le Co\u00ebnt","year":"2023","unstructured":"Le Co\u00ebnt Q, Legrand C, Rondeau V. Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data. Biostatistics. 2023;25(1):98\u2013116. https:\/\/doi.org\/10.1093\/biostatistics\/kxac044.","journal-title":"Biostatistics"},{"key":"4595_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. https:\/\/doi.org\/10.3389\/fphar.2017.00561.","journal-title":"Front Pharmacol"},{"issue":"6","key":"4595_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/d41573-022-00030-4","volume":"21","author":"S Upadhaya","year":"2022","unstructured":"Upadhaya S, Yu JX, Shah M, Campbell J, Hodge D. Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial field. Nat Rev Drug Discov. 2022;21(6):419\u201320. https:\/\/doi.org\/10.1038\/d41573-022-00030-4.","journal-title":"Nat Rev Drug Discov"},{"issue":"10294","key":"4595_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"22","key":"4595_CR37","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"issue":"9","key":"4595_CR38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"RJ Motzer","year":"2021","unstructured":"Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2026982.","journal-title":"N Engl J Med"},{"issue":"13","key":"4595_CR39","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"issue":"10212","key":"4595_CR40","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet"},{"issue":"10265","key":"4595_CR41","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9.","journal-title":"Lancet"},{"key":"4595_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1340979","volume":"15","author":"I Sala","year":"2024","unstructured":"Sala I, Pagan E, Pala L, et al. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2024;15:1340979. https:\/\/doi.org\/10.3389\/fimmu.2024.1340979.","journal-title":"Front Immunol"},{"key":"4595_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2020.07.017","volume":"148","author":"C Clement-Duchene","year":"2020","unstructured":"Clement-Duchene C, Carnin C, Guillemin F, Martinet Y. Surrogate endpoints for overall survival in lung cancer trials: a systematic review. Lung Cancer. 2020;148:1\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.017.","journal-title":"Lung Cancer"},{"issue":"2","key":"4595_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.2517-6161.1951.tb00088.x","volume":"13","author":"EH Simpson","year":"1951","unstructured":"Simpson EH. The interpretation of interaction in contingency tables. J R Stat Soc Series B Stat Methodol. 1951;13(2):238\u201341. https:\/\/doi.org\/10.1111\/j.2517-6161.1951.tb00088.x.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"11","key":"4595_CR45","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/sim.1616","volume":"23","author":"JPT Higgins","year":"2004","unstructured":"Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med. 2004;23(11):1663\u201382. https:\/\/doi.org\/10.1002\/sim.1616.","journal-title":"Stat Med"},{"issue":"12","key":"4595_CR46","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/j.ejca.2010.04.023","volume":"46","author":"JC Soria","year":"2010","unstructured":"Soria JC, Massard C, Le Chevalier T. Should progression-free survival remain the gold standard for oncology trials? Eur J Cancer. 2010;46(12):2279\u201383. https:\/\/doi.org\/10.1016\/j.ejca.2010.04.023.","journal-title":"Eur J Cancer"},{"issue":"3","key":"4595_CR47","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1177\/0962280214557578","volume":"26","author":"NR Latimer","year":"2017","unstructured":"Latimer NR, Abrams KR, Lambert PC, et al. Adjusting for treatment switching in randomised controlled trials. Stat Methods Med Res. 2017;26(3):1418\u201334. https:\/\/doi.org\/10.1177\/0962280214557578.","journal-title":"Stat Methods Med Res"},{"issue":"24","key":"4595_CR48","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1200\/JCO.2011.40.3824","volume":"30","author":"S Niraula","year":"2012","unstructured":"Niraula S, Seruga B, Ocana A, et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30(24):3028\u201337. https:\/\/doi.org\/10.1200\/JCO.2011.40.3824.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4595_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv370","volume":"108","author":"SY Zafar","year":"2016","unstructured":"Zafar SY. Financial toxicity of cancer care: it\u2019s time to intervene. J Natl Cancer Inst. 2016;108(5):djv370. https:\/\/doi.org\/10.1093\/jnci\/djv370.","journal-title":"J Natl Cancer Inst"},{"key":"4595_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102824","volume":"76","author":"A Mittal","year":"2024","unstructured":"Mittal A, Kim MS, Dunn S, Wright K, Gyawali B. Frequently asked questions on surrogate endpoints in oncology, opportunities, pitfalls, and the way forward. EClinicalMedicine. 2024;76:102824. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102824.","journal-title":"EClinicalMedicine"},{"key":"4595_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102283","volume":"65","author":"O Ciani","year":"2023","unstructured":"Ciani O, Manyara AM, Davies P, et al. A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials. EClinicalMedicine. 2023;65:102283. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102283.","journal-title":"EClinicalMedicine"},{"issue":"17","key":"4595_CR52","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","volume":"331","author":"ITT Liu","year":"2024","unstructured":"Liu ITT, Kesselheim AS, Cliff ERS. Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval. JAMA. 2024;331(17):1471\u20139. https:\/\/doi.org\/10.1001\/jama.2024.2396.","journal-title":"JAMA"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04595-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04595-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04595-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:51:38Z","timestamp":1792655498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04595-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":52,"alternative-id":["4595"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04595-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review and meta-analysis used only previously published data in the public domain and did not involve human participants or patient records; therefore, institutional review board approval and informed consent were not required per institutional and national guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}